State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.

Background: People who inject drugs (PWID) are especially vulnerable to harms from opioid use disorder (OUD). Medications for OUD (MOUD) effectively reduce overdose and infectious disease transmission risks.

Objective: We investigate whether state Medicaid coverage for methadone and buprenorphine is related to past-year MOUD use among PWID using cross-sectional, multilevel analyses with individual-level data on PWID from the Centers for Disease Control and Prevention's 2018 National HIV Behavioral Surveillance.

Teamwork Coaching in the Research Development Process.

Proposal teams play a critical, yet understudied, role in team science. This study advances our understanding of teamwork coaching in the research development (RD) process by analyzing proposal support in a U.S.

Development and Validation of a Brief Form of the Anticipated Effects of Food Scale.

Identifying malleable influences on eating behaviours will advance our ability to improve physical and mental health. Food-related emotional expectancies are the anticipated positive and negative emotions from eating different foods and are theorised to affect eating behaviour, and to be amenable to change. The Anticipated Effects of Food Scale (AEFS) assesses food-related emotional expectancies using 62 one-word items; however, a shorter questionnaire would be useful in large and clinical studies.

Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway.

To understand the potential benefits of emerging Alzheimer's disease (AD) therapies within and beyond clinical trial settings, there is a need to advance current outcome measurements into meaningful information relevant to all stakeholders. The relationship between the impact on disease biology and clinically measurable outcomes in cognition, function, and behavior must be considered when defining the meaningful benefit of early AD therapies. In this review, we discuss: (1) the lack of consideration for biomarkers in the current concept of meaningfulness in AD; (2) the lack of gold standards for determining minimal biologically and clinically important differences (MBCIDs) in AD trials; (3) how the treatment benefits of disease-modifying treatments are cumulative and increase over time; and (4) the different concepts of meaningfulness among key stakeholders.